Carcinotech

The company manufactures 3D bioprinted tumor models using patient-derived biopsies and established cell lines to support oncology drug discovery and preclinical testing. These models retain the native tumor microenvironment, including stromal and immune cell populations, to provide human-relevant data for evaluating therapies such as immunotherapies and chemotherapies. The services are targeted at biotech and pharmaceutical organizations seeking to improve clinical translation and optimize drug dosing strategies.